tbuckley/cabot-search huggingface dataset:
LEFT VENTRICULAR PSEUDOANEURYSM PRESENTING WITH PERICARDIAL EFFUSION: A RARE COMPLICATION OF MYOCARDIAL INFARCTION
Authors: Babar A. Khan, Nureddin Almaddah, Sania Khan, Farhan Ashraf, Raza Askari, Shadwan Alsafwah, Neeraja Yedlapati
Journal: Journal of the American College of Cardiology (2020)
ELECTROPHYSIOLOGY STUDY AND THE RISK OF MAJOR ARRHYTHMIC EVENTS IN BRUGADA SYNDROME: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Pattara Rattanawong, Jakrin Kewcharoen, Wasawat Vutthikraivit, Chanavuth Kanitsoraphan, Nway L. Ko Ko, Anusha Shanbhag, Win-Kuang Shen
Journal: Journal of the American College of Cardiology (2020)
INSULIN, LIXISENATIDE, AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME
Authors: David Aguilar, Marc A. Pfeffer, Brian Claggett, Jiankang Liu, John McMurray, Jean Claude Tardif, Kenneth Dickstein, Lars Kober, Rafael Diaz, Scott D. Solomon, Aramesh Saremi, Matthew Riddle
Journal: Journal of the American College of Cardiology (2020)
DOPPLER VERSUS CATHETER TRANSVALVULAR PRESSURE GRADIENTS IN SELF-EXPANDING VERSUS BALLOON EXPANDABLE TRANSCATHETER AORTIC VALVES, AN IN VITRO STUDY
Authors: Viktoria Stanova, Régis Rieu, Anne-Sophie Zenses, Josep Rodés-Cabau, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2020)
EARLY OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IN PATIENTS WITH PRIOR MEDIASTINAL RADIATION: A PROPENSITY MATCHED ANALYSIS
Authors: Riyad Yazan Kherallah, Darren Harrison, Katheryn Dougherty, Guilherme Silva, Ourania Preventza, Juan Carlos Plana, Stephanie Coulter, Neil Strickman, Ali Mortazavi, Raymond Stainback, Zvonimir Krajcer, Richard Fish, Joseph S. Coselli, Leo Simpson, Jennifer Cozart, Samar Sheth, Charles Hallman, Jose G. Diez, Kenneth Liao, Srikanth Koneru
Journal: Journal of the American College of Cardiology (2020)
NATIONAL TRENDS IN HOSPITALIZATIONS, MORTALITY AND COST OF CARE AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS IN THE UNITED STATES: NATIONWIDE INPATIENT SAMPLE FROM 2001 TO 2014
Authors: Gaurav Aggarwal, Apurva Patel, Saurabh Aggarwal, Mary Abed, Venkata Mahesh Alla
Journal: Journal of the American College of Cardiology (2020)
Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19
Authors: Huilan Zhang, Peng Zhou, Yanqiu Wei, Huihui Yue, Yi Wang, Ming Hu, Shu Zhang, Tanze Cao, Chengqing Yang, Ming Li, Guangyun Guo, Xianxiang Chen, Ying Chen, Mei Lei, Huiguo Liu, Jianping Zhao, Peng Peng, Cong-Yi Wang, Ronghui Du
Journal: Annals of Internal Medicine (2020)

Histopathologic Changes
LOW LEVEL OF HIGH SENSITIVITY C-REACTIVE PROTEIN AFTER PERCUTANEOUS CORONARY INTERVENTION PREDICTS RISK OF DEATH IN PATIENTS WITH MYOCARDIAL INFARCTION
Authors: Runzhen Chen, Chen Liu, Peng Zhou, Yu Tan, Sheng Zhaoxue, Jiannan Li, Jinying Zhou, Song Li, Hanjun Zhao, Hongbing Yan
Journal: Journal of the American College of Cardiology (2020)
Phase III trial of chemoprevention of lung carcinogenesis using green tea beverage and tea polyphenols (Polyphenon E)
Authors: L. L. Garland, H. S. Chow, J. Einspahr, R. B. Harris, J. Buckmeier, M. Tobar, S. Rodney, I. A. Hakim
Journal: Journal of Clinical Oncology (2006)

1026 Background: Oxidative reactions have been implicated as important modulators of human health and the development of disease, including cancer. Studies have shown an increased oxidant burden in chronic obstructive pulmonary disease, a disease state in which there is increased risk of lung cancer. Our overall goal is to develop a safe, feasible clinical research approach using non-invasive methods of biomarker retrieval that will serve as a model for lung cancer chemoprevention studies. The primary study objective is to determine the effects of high green tea consumption (beverage and Polyphenon E [Mitsui-Norin Co., Ltd., Shizuoka, Japan]) on biomarkers of oxidative stress that are putative modulators of lung cancer risk, including 8-hydroxydeoxyguanosine (protein oxidation), F2-isoprostanes (lipid oxidation), nitric oxide and antioxidant enzymes. Secondary objectives are to measure modulation of lung carcinogenesis-related genes in exfoliated bronchoepithelial cells. Methods: We are conducting a 6-month randomized, controlled, double-blind trial of beverage green tea or Polyphenon E capsules or a control intervention (matching double placebo) in former smokers (FS) with a ≥30 pack year smoking history and an FEV 1 ≤70%. Subjects are stratified by gender and inhaler use. Changes in oxidative damage are measured in exhaled breath condensate, blood and urine. Changes in gene expression of proliferative biomarkers (EGFR, PCNA, JUN, FOS, Ki-67) and apoptosis (bcl-2, caspase 3) are being assessed in induced sputum. Results: Recruitment and screening of subjects began 6/04. As of 12/05, 559 subjects have been phone screened for eligibility; of 99 eligible subjects, 54 were excluded by spirometry. 45 subjects have been enrolled and 25 have completed the study. No significant adverse events have been reported, including no liver toxicity. We have been able to extract RNA and measure gene expression in induced sputum. Conclusion: Six-month high tea consumption in FS with at least a moderate smoking history and FEV 1 ≤70% is feasible and safe. Recruitment is continuing. Supported by U01-CA-101204. No significant financial relationships to disclose.
UTILITY OF SERIAL QUANTIFICATION OF DELAYED PERICARDIAL HYPERENHANCEMENT IN RECURRENT PERICARDITIS: GREATEST BENEFIT DERIVED BY THOSE WITH HIGHEST BASELINE VALUES
Authors: Beni Rai Verma, Laurie Ann Moennich, Michael Chetrit, Kimi Sato, Arnav Kumar, Mohamed Khayata, Muhammad Furqan, Jarmanjeet Singh, Vivek Menon, Antoine Addoumieh, Bo Xu, Chadi Ayoub, Paul Cremer, Christine Louise Jellis, Deborah Kwon, Allan Klein
Journal: Journal of the American College of Cardiology (2020)
Mature data on neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy
Authors: M. Gaui, G. Amorim, R. Arcuri, G. Pereira, D. Moreira, C. Djahjah
Journal: Journal of Clinical Oncology (2006)

10603 Background: In Brazil, LABC remains a serious health problem, representing approx. 30% of all newly diagnosed breast cancers. Anthracycline-based neoadjuvant therapy is a standard treatment, but around 30% of pts do not respond. There is no standard approach in these refractory pts. In our institution, these pts receive RT, but almost half (46%) of pts are not rendered operable by RT alone. Because X is the reference treatment for anthracycline- and/or taxane-pretreated MBC and X and RT are supra-additive in in vivo models, there is a clear rationale for evaluating X-RT in this setting. Methods: Pts eligible for this prospective, open-label, single-center, non-randomized study had inoperable LABC refractory to FAC, ECOG PS ≥1 and adequate organ functions. Pts received RT 20c Gy/d ×5w (total dose 50Gy) plus X 850mg/m 2 bid orally d1–14, q3w for 2 cycles. Pts underwent surgery, if possible, after completion of neoadjuvant therapy. Pts with hormone receptor-positive tumors received tamoxifen after surgery. Results: Baseline characteristics of the 30 pts enrolled between Jan 2003 and May 2004: median age 47 years (range, 26–70); median ECOG PS 1; median tumor size (after anthracyclines) 80 cm 2 (range, 36–357cm 2 ); tumor grade II/III/unknown 20/37/43%; inflammatory carcinoma 21%. Two pts were excluded from this analysis as they received the incorrect X dosing regimen. 23/28 evaluable pts (82%) were operable after X-RT; 4 (14%) pts did not undergo surgery because of disease progression. Median tumor size after X-RT was 49 cm 2 (range, 6–196 cm 2 ). The median relative reduction in tumor size was 33%. After surgery, median residual tumor size was 12 cm 2 (range, 0−72) and the median number of positive nodes was 2 (range, 0−27). Pathological complete response was observed in 3 (11%) pts. The most common treatment-related adverse events (all grade 1/2) were mucositis, diarrhea, nausea and emesis. There were no grade 3/4 events. Conclusions: Our data indicate that neoadjuvant X-RT is feasible, well tolerated and appears more effective than RT alone in pts with LABC refractory to FAC, rendering a high proportion (82%) of pts eligible for surgery. No significant financial relationships to disclose.
BILATERAL RENAL ARTERIES STENTING USING CARBON DIOXIDE ANGIOGRAPHY IN COMBINATION WITH A MINIMAL IODINATED CONTRAST ANGIOGRAPHY IN PATIENT WITH REFRACTORY HYPERTENSION AND KIDNEY DISEASE
Authors: Hassan Alkhawam, Maryna Popp, Ammar Nasir, Michael Forsberg, Kartik Mani
Journal: Journal of the American College of Cardiology (2020)
Bisphosphonates for Osteopenia in Postmenopausal Women
Authors: Steven Snyder
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Older Adults With Subclinical Hypothyroidism
Authors: Jerome M. Hershman
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Feedback Loop Comprising EGF/TGFα Sustains TFCP2-Mediated Breast Cancer Progression
Authors: Yi Zhao, Neha Kaushik, Jae-Hyeok Kang, Nagendra Kumar Kaushik, Seung Han Son, Nizam Uddin, Min-Jung Kim, Chul Geun Kim, Su-Jae Lee
Journal: Cancer Research (2020)

Abstract Stemness and epithelial–mesenchymal transition (EMT) are two fundamental characteristics of metastasis that are controlled by diverse regulatory factors, including transcription factors. Compared with other subtypes of breast cancer, basal-type or triple-negative breast cancer (TNBC) has high frequencies of tumor relapse. However, the role of alpha-globin transcription factor CP2 (TFCP2) has not been reported as an oncogenic driver in those breast cancers. Here, we show that TFCP2 is a potent factor essential for EMT, stemness, and metastasis in breast cancer. TFCP2 directly bound promoters of EGF and TGFα to regulate their expression and stimulate autocrine signaling via EGFR. These findings indicate that TFCP2 is a new antimetastatic target and reveal a novel regulatory mechanism in which a positive feedback loop comprising EGF/TGFα and AKT can control malignant breast cancer progression. Significance: TFCP2 is a new antimetastatic target that controls TNBC progression via a positive feedback loop between EGF/TGFα and the AKT signaling axis.
Clinicopathologic characterization and prognostic factor in extraintestinal neuroendocrine tumors.
Authors: Eucario Leon Rodriguez, Sandra Ileana Perez Alvarez, Omar Macedo, Elizabeth Escobar
Journal: Journal of Clinical Oncology (2013)

e15131 Background: The frequency, prognostic factors and long-term survival of E-NET are poorly known. Methods: A retrospective analysis of clinical, histological characteristics and survival of patients with E-NET were done. Survival analyses were assessed by the Kaplan-Meier method and prognostic factors of overall survival were tested by uni/multivariate analysis. Results: Between 1997-2010, 241 patients were identified with NET. 31 Patients were E-NET (12.8%): median age was 55 years (16-79) and 55% were females. Primary location was lung, 58%, prostate 13%, breast 10%, urinary bladder 7%, and others 12%. At diagnosis 87% patients had symptoms and 52% were localized. A functioning tumor was in 7 patients (6 ACTH). Initial treatment was surgery 61%, chemotherapy 26% (23% had objective response) and palliative care 13%. After complete resection 4/14 patients recurred. With follow-up of 15months, the cancer-specific mortality was 55%. Overall 1- and 5-year survival were 72% and 35% respectively, which were lower than survival for GEP-NET (p=0.001, Figure 1). 5 year survival differed significantly according to age at diagnosis (47% ≤50 vs 27% &gt;50 years); location (60% lung vs 10% non-lung); extension (58% localized vs 15% metastatic/locally advanced); stage at diagnosis (59% stage I-II vs 13% III-IV); histology (52% NET/carcinoid vs 14% NEC); degree of differentiation (44% well/moderately vs 0% poorly differentiated); initial treatment (55% surgery, 25% palliative care and 0% chemotherapy); and recurrence (100% absent vs 25% present). In univariate analysis, the negative prognostic factors were age &gt;50 years, no lung site, symptomatic, metastatic/locally advanced disease, extrahepatic metastases, NEC, poor differentiation and recurrence. In multivariate analysis, only age &gt;50 years was an independent predictor of survival (p=0.027). Conclusions: In our experience, E-NET represent 13% of all the NET. Present symptoms with a fewer frequency, are less functional, have more frequently metastases, and a worst prognosis (5-year survival 34 vs 72%). The most important prognostic factor for overall survival was age &gt;50 years.
Inflammation in Heart Failure
Authors: Sean P. Murphy, Rahul Kakkar, Cian P. McCarthy, James L. Januzzi
Journal: Journal of the American College of Cardiology (2020)

It has long been observed that heart failure (HF) is associated with measures of systemic inflammation. In recent years, there have been significant advancements in our understanding of how inflammation contributes to the pathogenesis and progression of HF. However, although numerous studies have validated the association between measures of inflammation and HF severity and prognosis, clinical trials of anti-inflammatory therapies have proven mostly unsuccessful. On this backdrop emerges the yet unmet goal of targeting precise phenotypes within the syndrome of HF; if such precise definitions can be realized, and with better understanding of the roles played by specific inflammatory mediators, the expectation is that targeted anti-inflammatory therapies may improve prognosis in patients whose HF is driven by inflammatory pathobiology. Here, the authors describe mechanistic links between inflammation and HF, discuss traditional and novel inflammatory biomarkers, and summarize the latest evidence from clinical trials of anti-inflammatory therapies.
LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.
Authors: Craig B. Reeder, Rodger Edwin Tiedemann, Katherine Gano, Amylou C. Dueck, Christoher R Conley, Stephen Maxted Ansell, Grzegorz S. Nowakowski, Kelly Kevelin Curtis, John Kelly Camoriano, Jose Francisco Leis, James L. Slack, Riccardo Valdez, A. Keith Stewart, Thomas E. Witzig
Journal: Journal of Clinical Oncology (2012)

8053 Background: Lenalidomide (LEN) is an immunomodulatory agent that has shown significant single-agent anti-lymphoma activity in patients with relapsed disease and in combination may enhance the efficacy of rituximab by various mechanisms. There is limited data on the role of LEN in combination regimens for treatment-naïve patients. This phase II single arm trial was designed to evaluate tumor response, toxicity (AE) and survival with a combination of LEN, rituximab, cyclophosphamide (CTX) and dexamethasone (DEX) (LR-CD) in symptomatic untreated patients with low grade B-cell non-Hodgkin lymphoma. Methods: Eligibility required age ≥18, ECOG PS ≤2, confirmed diagnosis of low-grade B-cell lymphoma (FL1-2, SLL, MZL or LPL/WM), measurable nodes ≥2cm or IgM ≥400mg/dL(LPL/WM), ANC ≥1400/mm 3 , platelets ≥100,000/mm 3 , creatinine ≤2mg/dL, signed informed consent and in need of therapy. Treatment consisted of IV rituximab 375mg/m 2 D1, oral LEN 20mg D1-21, CTX 250mg/m 2 D1, 8, 15, DEX 40mg D1, 8, 15, 22 and ASA 325 mg daily in a 28 day cycle. Treatment continued 2 cycles beyond best response (max 12). Toxicity was assessed by NCI CTCAE v3.0. Results: 28 patients have enrolled at Mayo Clinic with 25 evaluable for toxicity and 21 for response: Median age 65(43-83), 72% male, FL 24%, MZL 28%, LPL/WM 38%, and SLL 4%. Median number of cycles given was 5. Overall response in 21 patients with response data is 95% (95% CI 76-100%) with 19% CR (95% CI 5-42%), and 76% PR (confirmed and unconfirmed, 95% CI 53-92%). The ORR in 8 patients with LPL/WM with response data was 88%, all PR (95% CI 47-100%). At a median f/u of 14.7 months 96% are alive without progression. 1 death (unrelated) occurred 7.7 months after completing 12 cycles of treatment. The most common grade ≥3 AEs were neutropenia (37.5%), leukopenia (16.7%), anemia (12.5%) and fatigue (12.5%). Conclusions: The combination LR-CD with the novel agent LEN is feasible, well tolerated and produces high response rates in symptomatic patients with low grade B-cell NHL. Toxicities are manageable and similar to reported data of single agent LEN.
Lipoadenoma of the Parathyroid Gland: Characterization of an Institutional Series Spanning 28 Years
Authors: C. Christofer Juhlin, Henrik Falhammar, Jan Zedenius, Inga-Lena Nilsson, Anders Höög
Journal: Endocrine Pathology (2020)

Abstract Parathyroid lipoadenomas (PLAs) are rare tumors, and case descriptions are limited, &lt; 80 to date. As a consequence, scarce information regarding the etiology of these enigmatic lesions is available. We searched our departmental pathology database for PLAs diagnosed between 1992 and 2020, reexamined the histology of each case, and recorded clinical parameters from the patients’ medical charts. As the diagnostic criteria of this lesion vary over this time period, we defined PLA as an enlarged parathyroid gland with &gt; 50% fat on histologic examination with preoperative evidence of primary hyperparathyroidism (PHPT). A total of 8 bona fide PLA cases and 2 equivocal PLAs (close to 50% fat) were included. As approximately 4000 conventional parathyroid adenomas were diagnosed at our department during the same time interval, the prevalence of PLA was 0.20%. PLA patients were predominately female (63%) and presented with classical PHPT-related symptoms. Majority of cases were successfully located preoperatively and had an average tumor weight of 445 mg. Histologically, all PLAs consisted of &gt; 50% mature adipose tissue, except a single case with brown fat. Of note, PLA patients exhibited a body mass index in line with PHPT patients in general, but a relatively high, near-significant prevalence of arterial hypertension was observed when compared to tumors with less fat ( P = 0.0584). Future studies on this finding might be warranted. To summarize, we present one of the largest institutional PLA case series to date, and conclude that PLAs are rare, sporadic tumors mirroring many clinical aspects of conventional adenomas—with a potential coupling to hypertension worthy of follow-up studies.
Sparse Data–Driven Learning for Effective and Efficient Biomedical Image Segmentation
Authors: John A. Onofrey, Lawrence H. Staib, Xiaojie Huang, Fan Zhang, Xenophon Papademetris, Dimitris Metaxas, Daniel Rueckert, James S. Duncan
Journal: Annual Review of Biomedical Engineering (2020)

Sparsity is a powerful concept to exploit for high-dimensional machine learning and associated representational and computational efficiency. Sparsity is well suited for medical image segmentation. We present a selection of techniques that incorporate sparsity, including strategies based on dictionary learning and deep learning, that are aimed at medical image segmentation and related quantification.
Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018
Authors: Nana Wilson, Mbabazi Kariisa, Puja Seth, Herschel Smith, Nicole L. Davis
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

From 2017 to 2018, U.S. overdose death rates involving synthetic opioids (excluding methadone) increased by 10%, death rates involving heroin decreased by 4%, and prescription opioid-involved overdose death rates decreased by 13.5%.
FEASIBILITY OF CT ANGIOGRAM IN CORONARY ARTERY DISEASE CLEARANCE FOR PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Homam Ibrahim, Danielle Sin, Samantha Vidal, Illya Pushkar, Carlos Andres Gonzalez-Lengua, Jorge Fuentes, Hasan Jilaihawi, Cezar Staniloae, Mathew Williams
Journal: Journal of the American College of Cardiology (2020)
Bariatric Surgery in Patients With Obesity and Latent Autoimmune Diabetes in Adults (LADA)
Authors: Ali Aminian, Gautam Sharma, Rickesha L. Wilson, Sangeeta R. Kashyap, Emanuele Lo Menzo, Samuel Szomstein, Raul J. Rosenthal, Philip R. Schauer, Roman Vangoitsenhoven
Journal: Diabetes Care (2020)

Bariatric surgery induces weight loss and restores glucose metabolism in patients with obesity and type 2 diabetes (T2D) (1). In patients with autoimmune diabetes that eventually results in β-cell failure, the glycemic effects of bariatric surgery are limited (2). Adult patients with latent autoimmune diabetes in adults (LADA) have a slower decline in β-cell function and lower requirement for insulin therapy than patients with classical young-onset type 1 diabetes (T1D) (3). They are often misdiagnosed as having T2D and might have unrealistic expectations of diabetes remission after bariatric surgery with additional risk for development of postoperative diabetic ketoacidosis (DKA) (4). The safety and efficacy of bariatric surgery in patients with obesity and LADA have not been characterized.

We retrospectively analyzed medical records of patients with obesity and LADA who underwent bariatric surgery at the Cleveland Clinic Health System in the U.S. LADA status was defined as adult-onset diabetes with presence of GAD antibodies. We compared pre- and postsurgery BMI, glycemic control (HbA1c), daily insulin dose, and blood pressure and lipid profile using a paired Student t test, with a P value of 0.05 considered significant.

Between October 2006 and March 2018, nine female patients underwent laparoscopic bariatric surgery (five Roux-en-Y gastric bypass and four sleeve gastrectomy) and one male patient underwent sleeve gastrectomy. The median age at …
RIGHT VENTRICULAR DEFORMITY AND FIBROSIS IN SUBJECTS WITH PULMONARY HYPERTENSION
Authors: Nilda Espinola-Zavaleta, Neftali E. Antonio-Villa, Diego Javier Oregel Camacho, Gyselle Camacho-Camacho, Ricardo Alvarez-Santana, Alberto Aranda-Fraustro, Erick Alexanderson-Rosas
Journal: Journal of the American College of Cardiology (2020)